BACKGROUND: We examined the activation pattern of extracellular signal-regulated kinase 1 and 2 (ERK1/2) and its dependence on D1 versus D2 dopamine receptors in hemiparkinsonian rats treated with 3,4-dihydroxyphenyl-L-alanine (L-DOPA). METHODS: 6-Hydroxydopamine-lesioned rats were treated acutely or chronically with L-DOPA in combination with antagonists for D1 or D2 receptors. Development of dyskinesia was monitored in animals receiving chronic drug treatment. Phosphorylation of ERK1/2, mitogen- and stress-activated protein kinase-1 (MSK-1), and the levels of FosB/DeltaFosB expression were examined immunohistochemically. RESULTS: L-DOPA treatment caused phosphorylation of ERK1/2 in the dopamine-denervated striatum after acute and chronic administration. Similar levels were observed in matrix and striosomes, and in enkephalin-positive and dynorphin-positive neurons. The severity of dyskinesia was positively correlated with phospho-ERK1/2 levels. Phosphorylation of ERK1/2 and MSK-1 was dose-dependently blocked by SCH23390, but not by raclopride. SCH23390 also inhibited the development of dyskinesia and the induction of FosB/DeltaFosB. CONCLUSIONS: L-DOPA produces pronounced activation of ERK1/2 signaling in the dopamine-denervated striatum through a D1-receptor-dependent mechanism. This effect is associated with the development of dyskinesia. Phosphorylated ERK1/2 is localized to both dynorphinergic and enkephalinergic striatal neurons, suggesting a general role of ERK1/2 as a plasticity molecule during L-DOPA treatment.
BACKGROUND: We examined the activation pattern of extracellular signal-regulated kinase 1 and 2 (ERK1/2) and its dependence on D1 versus D2 dopamine receptors in hemiparkinsonian rats treated with 3,4-dihydroxyphenyl-L-alanine (L-DOPA). METHODS:6-Hydroxydopamine-lesioned rats were treated acutely or chronically with L-DOPA in combination with antagonists for D1 or D2 receptors. Development of dyskinesia was monitored in animals receiving chronic drug treatment. Phosphorylation of ERK1/2, mitogen- and stress-activated protein kinase-1 (MSK-1), and the levels of FosB/DeltaFosB expression were examined immunohistochemically. RESULTS:L-DOPA treatment caused phosphorylation of ERK1/2 in the dopamine-denervated striatum after acute and chronic administration. Similar levels were observed in matrix and striosomes, and in enkephalin-positive and dynorphin-positive neurons. The severity of dyskinesia was positively correlated with phospho-ERK1/2 levels. Phosphorylation of ERK1/2 and MSK-1 was dose-dependently blocked by SCH23390, but not by raclopride. SCH23390 also inhibited the development of dyskinesia and the induction of FosB/DeltaFosB. CONCLUSIONS:L-DOPA produces pronounced activation of ERK1/2 signaling in the dopamine-denervated striatum through a D1-receptor-dependent mechanism. This effect is associated with the development of dyskinesia. Phosphorylated ERK1/2 is localized to both dynorphinergic and enkephalinergic striatal neurons, suggesting a general role of ERK1/2 as a plasticity molecule during L-DOPA treatment.
Authors: Manolo Carta; Hanna S Lindgren; Martin Lundblad; Roberto Stancampiano; Fabio Fadda; M A Cenci Journal: J Neurochem Date: 2006-03 Impact factor: 5.372
Authors: J P Doucet; Y Nakabeppu; P J Bedard; B T Hope; E J Nestler; B J Jasmin; J S Chen; M J Iadarola; M St-Jean; N Wigle; P Blanchet; R Grondin; G S Robertson Journal: Eur J Neurosci Date: 1996-02 Impact factor: 3.386
Authors: Christine Konradi; Jenny E Westin; Manolo Carta; Molly E Eaton; Katarzyna Kuter; Andrzej Dekundy; Martin Lundblad; M Angela Cenci Journal: Neurobiol Dis Date: 2004-11 Impact factor: 5.996
Authors: K Elisabet Ohlin; Irene Sebastianutto; Chris E Adkins; Cornelia Lundblad; Paul R Lockman; M Angela Cenci Journal: Neuroimage Date: 2012-03-03 Impact factor: 6.556
Authors: Tanya Chotibut; Samantha Meadows; Ella A Kasanga; Tamara McInnis; Mark A Cantu; Christopher Bishop; Michael F Salvatore Journal: Mov Disord Date: 2017-06-20 Impact factor: 10.338
Authors: Yunmin Ding; Lisa Won; Jonathan P Britt; Sean Austin O Lim; Daniel S McGehee; Un Jung Kang Journal: Proc Natl Acad Sci U S A Date: 2010-12-27 Impact factor: 11.205
Authors: Kristin B Dupre; Corinne Y Ostock; Karen L Eskow Jaunarajs; Thomas Button; Lisa M Savage; William Wolf; Christopher Bishop Journal: Exp Neurol Date: 2011-02-22 Impact factor: 5.330
Authors: Jill R Crittenden; Ippolita Cantuti-Castelvetri; Esen Saka; Christine E Keller-McGandy; Ledia F Hernandez; Lauren R Kett; Anne B Young; David G Standaert; Ann M Graybiel Journal: Proc Natl Acad Sci U S A Date: 2009-01-26 Impact factor: 11.205
Authors: A A Martinez; M G Morgese; A Pisanu; T Macheda; M A Paquette; A Seillier; T Cassano; A R Carta; A Giuffrida Journal: Neurobiol Dis Date: 2014-12-05 Impact factor: 5.996
Authors: Kristin B Dupre; Corinne Y Ostock; Jessica A George; Karen L Eskow Jaunarajs; Cara M Hueston; Christopher Bishop Journal: ACS Chem Neurosci Date: 2013-04-01 Impact factor: 4.418